Omeza® News

Approved Abstract: A Retrospective Observational Evaluation of OCM as Primary Therapy for a Thermal Burn Wound in an Adult Private Practice Wound Setting. The abstract will be presented at the 2026 Fall SAWC Conference, in Las Vegas, NV by Dr. Angelina Ferguson. Dr. Ferguson is the Chief Research Officer for Sygnola Research. Sygnola Research Headquarters […]

NEWS PROVIDED BYOMEZA LLCAug 17, 2026, 07:58 ET Transforming Wound Care Through Marine Science Omeza® Holdings, Inc. is a U.S.-basedocean biotechnology company developing and commercializing marine-derived peptides andlipid products, with an FDA-cleared product, OCM™, already on the market and ongoingclinical programs to expand reimbursement and indications. Omeza products are formulated andmanufactured in the USA. SARASOTA, […]

SARASOTA, Fla., Aug. 13, 2026 /PRNewswire-PRWeb/ — [OMEZA] today announced it has been ranked No. 230th on the 2026 Inc. 5000 list, the annual list of the fastest-growing private companies in America. The list is the most prestigious ranking of the nation’s most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving […]

Round positions Omeza to accelerate clinical development and scale nationwide commercialization of its FDA-cleared regenerative wound care platform Sarasota, FL – April 16th, 2026 – Omeza Holdings, Inc. (“Omeza”), a commercial-stage advanced wound care company with an FDA-cleared regenerative product already marketed in the U.S., today announced the closing of an $8.5 million Series A […]